MedPath

iquid Biopsies for minimally invasive Detection of Acute Rejectio

Completed
Conditions
orgaantransplantatie
graft rejection
transplant rejection
Registration Number
NL-OMON50673
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
450
Inclusion Criteria

Adult kidney transplant recipients (>= 18 years of age) receiving a kidney
transplant of either a living or deceased donor in the Erasmus MC.

Exclusion Criteria

Below 18 years of age

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary endpoint of this explorative study is the ability to identify kidney<br /><br>allograft rejection by markers in blood and/or urine; i.e. level of dd-cfDNA,<br /><br>presence of specific nucleosome variants, circulating endothelial cells and the<br /><br>presence of EVs. Therefore, the outcome of the proposed markers will be<br /><br>correlated with the currently used methods which are the kidney biopsy, serum<br /><br>creatinine and urinary protein concentrations.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary the proposed markers will be correlated with the urinary<br /><br>concentrations of CXCL9 and CXCL10, which are promising upcoming non-invasive<br /><br>markers for allograft rejection. In exploratory analyses, we will try to<br /><br>identify the best marker or combination of markers to diagnose kidney<br /><br>transplant rejection. </p><br>
© Copyright 2025. All Rights Reserved by MedPath